The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.
In an effort to clarify the clinical significance of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA), we examined the prevalence of anti-cardiolipin antibodies (aCL), anti-beta2-glycoprotein I antibodies (anti-beta2-GPI), antiprothrombin antibodies (anti-PT), and anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) in 175 patients with systemic lupus erythematosus (SLE) comprising 67 patients with thrombotic complications. The present study showed that positive results of anti-beta2-GPI-ELISA and anti-PS/PT-ELISA could serve as markers of thrombotic complications in patients with SLE, whereas aCL and anti-PT are less reliable as markers of these complications. Furthermore, results of the anti-PS/PT-ELISA correlate best with the occurrence of both arterial and venous thrombosis in patients with SLE.
Nojima
Junzo
J
Laboratory for Clinical Investigation, Osaka University Hospital, Suita, Osaka 565-0871, Japan. nojima@hplab.med.osaka-u.ac.jp
Iwatani
Yoshinori
Y
Suehisa
Etsuji
E
Kuratsune
Hirohiko
H
Kanakura
Yuzuru
Y
D000026:Abortion, Habitual / Q000209:etiology / Q000276:immunology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010718:Phosphatidylserines / Q000276:immunology; D015539:Platelet Activation / Q000187:drug effects; D011247:Pregnancy; D011516:Prothrombin / Q000276:immunology; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000209:etiology* / Q000276:immunology; D020246:Venous Thrombosis / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies; D001324:Autoantigens; D006023:Glycoproteins; D007074:Immunoglobulin G; D010718:Phosphatidylserines; D053482:beta 2-Glycoprotein I; D000244:Adenosine Diphosphate; D011516:Prothrombin